For half a century, pancreatic cancer has crushed hope with brutal efficiency. Patients received diagnoses that sounded like death sentences. Doctors watched treatments fail within months. Survival rates barely budged despite billions spent on research. Something just changed.
Join a community of 14,000,000+ Seekers!
Subscribe to unlock exclusive insights, wisdom, and transformational tools to elevate your consciousness. Get early access to new content, special offers, and more!
A team in Spain reports results that oncologists have chased for decades but never achieved. Pancreatic tumors in mice didn’t just shrink. They disappeared completely. And here’s what makes headlines around the world: they stayed gone. No relapse. No resistance. No precedent.
Mariano Barbacid, head of the Experimental Oncology Group at Spain’s National Cancer Research Centre (CNIO), led the work published in Proceedings of the National Academy of Sciences. His team attacked pancreatic cancer with a strategy so different from standard approaches that it rewrote what seemed possible.
But before celebrating, understand what this means and what it doesn’t. Mice are not humans. Lab success is not a cure. Clinical trials remain distant, and Barbacid himself urges caution.
Yet after 50 years of watching pancreatic cancer win almost every battle, direction matters. And for the first time in generations, that direction points somewhere new.
Why Pancreatic Cancer Almost Always Wins
Pancreatic ductal adenocarcinoma kills with speed and stealth. Detection usually comes late, when options narrow to slim and slimmer. In Spain alone, more than 10,300 people receive this diagnosis each year. Across the Western world, fewer than 10 percent survive five years.
Medical advances that transformed breast cancer and melanoma barely touched pancreatic cancer. Chemotherapy from the 1990s remained the best option for decades. Patients and families faced statistics that hadn’t improved since their grandparents’ generation.
Scientists knew why. A mutated gene called KRAS drives roughly 90 percent of pancreatic cancers. For years, researchers considered KRAS “undruggable,” a molecular target too slippery to hit with precision.
That belief finally cracked in 2021. Drugs targeting KRAS mutations gained approval, sparking cautious optimism. Tumors responded initially. Survival improved by months.
Then cancer found a way around the drugs. Resistance emerged fast, usually within months. Tumors roared back. Patients died anyway.
Each failed treatment taught researchers the same harsh lesson. Block KRAS at one point, and cancer simply reroutes through alternative pathways. A single lock won’t secure a door if the hinges remain exposed.
Barbacid understood this problem better than most. Decades ago, he helped identify the first human oncogene. He developed some of the earliest animal models for pancreatic cancer. He spent years watching promising approaches collapse under the weight of resistance.
His latest work stems from a simple question: what if resistance could be designed out of the system entirely?
Breaking the Beam at Three Points
Barbacid’s team pursued a strategy that sounds obvious in retrospect but required extraordinary precision to execute. Instead of attacking KRAS signaling at a single molecular point, they targeted three simultaneously.
Picture a beam attached to a ceiling. Fix it at one point, and breaking it takes minimal force. Fix it at three points, and suddenly, destruction requires far more energy than cancer can muster.
Applied to biology, this meant selecting three drugs that each blocked different parts of the KRAS pathway. Cancer cells couldn’t simply reroute around one obstacle when three existed at once.
Daraxonrasib, an experimental KRAS inhibitor, formed the first component. Afatinib, already approved for certain lung cancers, served as the second by blocking EGFR receptors. SD36, a protein degrader targeting STAT3, completed the combination.
Each drug alone produced modest effects. Dual combinations slowed tumor growth but didn’t stop it. Only the triple therapy achieved something unprecedented.
Tumors in three different mouse models of pancreatic cancer underwent what the research paper describes as “robust regression of experimental PDACs and avoids the onset of tumor resistance.”
Regression means shrinkage. Robust means dramatic. But the phrase “avoids the onset of tumor resistance” carries the real weight. Cancer didn’t adapt. It died.
Complete Tumor Elimination in Mouse Models
Barbacid’s team tested their approach across multiple experimental scenarios. Orthotopic tumors, where cancer cells grow in the actual pancreas location, responded first. Genetically engineered mouse models, which more faithfully reproduce human disease progression, came next.
Results remained consistent. Within three to four weeks of starting treatment, tumors vanished from ultrasound scans. Microscopic examination of pancreatic tissue after 300 days revealed something equally striking: no tumor cells remained. Neither did the dense, fibrous stroma that typically surrounds pancreatic tumors. Even the structural scaffolding that cancer builds to support its growth had disappeared. Healthy pancreatic tissue replaced every trace of disease.
Mice treated with the triple therapy lived over 200 days without relapse. Control mice, receiving no treatment, survived barely 40 days. Mice treated with daraxonrasib alone lived longer than controls but eventually succumbed when resistance developed. Only the three-drug combination prevented cancer’s comeback.
Safety results mattered as much as effectiveness. Aggressive cancer treatments often destroy tumors while devastating healthy tissue. Patients trade cancer for organ damage, immune collapse, or other life-threatening toxicities.
Barbacid’s mice maintained normal body weight throughout treatment. Blood counts stayed stable. Organs showed no signs of damage. Intestinal tissue, kidney function, and metabolic parameters remained within normal ranges.
Eliminating cancer without destroying the patient is not just desirable. It’s essential for any therapy hoping to reach human trials.
How the Triple Therapy Actually Works
Each drug in Barbacid’s combination serves a specific purpose, blocking KRAS signaling at different molecular nodes.
Daraxonrasib attacks KRAS directly. As a RAS(ON) inhibitor, it blocks multiple KRAS mutations, not just one specific variant. Cancer cells depend on KRAS to transmit growth signals. Daraxonrasib interrupts that transmission.
But cancer cells respond by amplifying signals through EGFR receptors, which sit upstream in the pathway. Afatinib shuts down both EGFR and its related receptor HER2, cutting off that escape route.
When both KRAS and EGFR are blocked, cancer cells activate STAT3, a transcription factor that controls cell survival through a separate pathway. Barbacid’s research identified STAT3 activation as the mechanism behind resistance in tumors that otherwise responded to dual therapy.
SD36 degrades STAT3 proteins before they can rescue dying cancer cells. With all three pathways blocked, tumor cells have nowhere to turn. They undergo apoptosis, programmed cell death, en masse.
Dual combinations failed because cancer only needs one functional signaling node to survive. Block two, and the third keeps tumors alive. Block all three, and cancer runs out of options.
Researchers confirmed this by testing genetic ablation of RAF1, EGFR, and STAT3 genes in mouse tumor cells. Removing any two genes slowed growth but didn’t kill cells. Removing all three triggered immediate cell death. Pharmacological inhibition mirrored genetic results. Biology rarely offers such clear validation.
Patient-Derived Tumors Also Responded
Mouse tumor models provide controlled environments for testing new therapies. But human cancers carry additional mutations, heterogeneity, and unpredictability. Many treatments that work beautifully in mouse models fail when confronting actual human disease.
Barbacid’s team addressed this by testing patient-derived xenografts (PDX). These models use actual human tumor tissue, either grown briefly in culture or transplanted directly from surgical specimens into immunocompromised mice.
Seven different PDX models entered the study, each carrying unique mutation profiles beyond the common KRAS driver. Some harbored TP53 mutations. Others included SMAD4 or CDKN2A alterations. Each represented a distinct genetic variant of pancreatic cancer.
Results across PDX models matched those from mouse tumors. Treatment with daraxonrasib, afatinib, and SD36 induced complete tumor regression within 60 days. Mice remained tumor-free for over 200 days after treatment stopped.
Small cysts lined with benign ductal cells appeared in some treated mice, but these showed no proliferation and no signs of malignancy. Essentially, cancer transformed into harmless tissue that posed no threat.
PDX studies revealed another crucial finding. Because these experiments used immunodeficient mice lacking mature T cells, tumor regression didn’t depend on adaptive immunity. Barbacid’s triple therapy worked through direct effects on cancer cells, not by turbocharging immune responses.
That matters for designing human trials, where immune status varies widely among patients already weakened by disease.
Not Ready for Human Trials Yet
Barbacid refuses to oversell his findings. When asked about next steps, he states clearly: “we are not yet in a position to carry out clinical trials with this triple therapy.”
Multiple obstacles stand between mouse success and human application. Daraxonrasib shows promise but remains experimental. Afatinib carries FDA approval only for specific lung cancers, and the dose used in mice far exceeds what humans currently tolerate for pancreatic cancer treatment.
SD36, despite working beautifully in animal models, has poor pharmacological properties that make human use impractical. Researchers need orally available STAT3 degraders with better absorption and distribution profiles.
Optimizing dosing schedules presents another challenge. Mice received daily treatments for weeks. Human treatment regimens must balance effectiveness against cumulative toxicity, drug interactions, and patient quality of life.
Clinical trial design will require extensive preliminary work. Which patients benefit most? Should treatment start immediately after diagnosis or wait until after surgery? How long should therapy continue?
These questions lack easy answers. As Barbacid’s team writes in their paper, the road to clinical application “pave the way for the design of combined therapies that may improve survival,” but reaching that destination will demand patience and rigorous testing.
Still, direction counts. Before this work, pancreatic cancer research cycled through variations on the same failed approaches. Now scientists have proof that resistance isn’t inevitable. It can be prevented through intelligent combination strategies that leave cancer with no escape routes.
What Changed After 50 Years
Pancreatic cancer has humbled researchers for generations. Brilliant scientists devoted their careers to finding better treatments. Pharmaceutical companies invested fortunes in drug development. Patients enrolled in clinical trials, hoping their participation might save others, even when their own prognosis looked grim. Progress came slowly, measured in weeks of extended survival rather than years of extended life.
Barbacid’s work doesn’t guarantee cures. It doesn’t mean pancreatic cancer becomes manageable next year or even in five years. But it accomplishes something equally valuable.
It proves that resistance, long considered an inevitable consequence of targeted therapy, can be designed out of the system. Cancer adapts quickly, but humans can think faster. By anticipating resistance mechanisms before they emerge, scientists can block every exit simultaneously.
Other cancers might learn from this approach. Lung cancer, colorectal cancer, and melanoma all face resistance challenges. If pancreatic cancer, among the most aggressive malignancies known, can be stopped by multi-point targeting, perhaps other tumors will yield to similar strategies.
Barbacid himself is 77 years old. He discovered the first human oncogene in 1982. He could have retired decades ago with a secure. Instead, he kept working, kept refining mouse models, kept testing combinations until something worked.
That persistence, multiplied across thousands of researchers in hundreds of labs, drives medical progress forward incrementally until suddenly, after 50 years, a wall becomes a door.
What Beating Cancer Teaches Us About Being Human
When scientists break through a 50-year deadlock, when they make tumors vanish that were thought unbeatable, something shifts in how we understand our place in a universe that often feels indifferent to our suffering.
Life on Earth suddenly looks different through that lens. We are not passive observers watching disease unfold according to fixed rules. We are pattern-finders, problem-solvers who can rewrite outcomes that seemed written in stone. Every cell in a tumor follows biological laws, yes. But so does every neuron firing in a scientist’s brain as they imagine a new approach.
Barbacid, now in his seventies, helped discover the first human oncogene decades ago. He could have stopped there. He chose to keep pushing. Human potential reveals itself not in single moments of genius but in sustained refusal to accept defeat. We build knowledge slowly, brick by brick, failure by failure, until suddenly a wall becomes a door.
What readers should take from findings like these extends beyond medicine. We live in a cosmos where entropy tends toward disorder, where complexity breaks down, and where life itself seems improbable. Yet here we are, not just surviving but actively reshaping the biological world around us and within us.
Pancreatic cancer will still kill people this year. Clinical trials remain distant. But distant is not impossible. Every boundary we break teaches us we are more than we thought. Not gods, not conquerors of nature, but participants in an ongoing negotiation between what is and what could be.
Maybe our sense of purpose comes from exactly that. From knowing we can look at a problem that has destroyed millions of lives and say, “not forever.” From proving, over and over across every field of human effort, that what seems fixed can change if we think hard enough about how to change it.
Mice are not humans. Lab results are not cures. But after half a century of going nowhere, pancreatic cancer research now points somewhere new. And that somewhere was built by people who believed their work mattered even when results refused to come.
Human consciousness may be the universe’s way of looking at itself and deciding to do something about the parts it doesn’t like. Cancer exists because cells mutate. Cancer treatment exists because we decided mutation was not the final word. Which impulse defines us more?
30
0
1.57m
0
